Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
Rhea-AI Summary
Nexalin Technology (Nasdaq: NXL) announced an exclusive distribution agreement with Carmi Masha Technologies Ltd. to market and sell Nexalin’s Gen-2 SYNC 15 mA non-invasive neurostimulation console in Israel.
The agreement follows regulatory approval by the Israeli Ministry of Health authorizing commercial sale for indications including insomnia, depression, and anxiety. Carmi Masha will handle importation, registration, sales, marketing, clinical education, and distribution to hospitals, clinics, and private centers.
The companies also plan to explore future clinical applications for PTSD, TBI, Alzheimer’s, and dementia as part of ongoing global clinical initiatives.
Positive
- Regulatory approval from Israeli Ministry of Health for Gen-2 SYNC
- Exclusive distributor agreement with Carmi Masha for Israel
- Carmi Masha to manage sales, marketing, and clinical education nationally
- Commercial access to hospitals, clinics, and private centers in Israel
Negative
- Approval confined to Israel; not a multi-country clearance
- No commercial launch date, pricing, or initial sales projections disclosed
Appointment Follows Israeli Ministry of Health Approval for Nexalin’s Gen-2 SYNC Device
HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. (“Carmi Masha”), a leading Israeli medical device distributor, to market and sell Nexalin’s Gen-2 Console (“SYNC”), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel.
This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin’s Gen-2 SYNC device in Israel for the treatment of a variety of mental health disorders, such as insomnia, depression, and anxiety. Nexalin and Carmi Masha also plan to explore potential future applications of the technology in post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), Alzheimer’s disease, and other forms of dementia as part of the Company’s ongoing global clinical initiatives. Under the terms of the agreement, Carmi Masha will lead all sales, marketing, and clinical education efforts in Israel, as well as manage the importation, registration, and distribution of Nexalin’s SYNC device across hospitals, clinics, and private treatment centers.
Mark White, CEO of Nexalin Technology, stated, “We are pleased to partner with Carmi Masha Technologies, a company with deep experience in introducing innovative neuro and medical technologies to the Israeli market. With regulatory approval now secured, this exclusive agreement enables us to rapidly initiate commercial activities in Israel and begin providing patients and healthcare providers access to our non-invasive, drug-free technology. This partnership represents another step forward in our broader strategy to expand Nexalin’s global footprint in high-value international markets, as well as strengthen our footprint across the Middle East.”
Mr. Alex Harel, CEO of Carmi Masha Technologies Ltd., commented, “We are excited to collaborate with Nexalin to introduce this innovative neurostimulation platform to Israel. Nexalin’s SYNC device offers a safe, non-invasive solution that aligns perfectly with the growing demand for effective, drug-free treatments for mental health disorders. We look forward to working with Nexalin to bring this important therapy to patients across the country.”
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic frequency-based medical technology to treat mental health issues. Evidence indicates Nexalin’s neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its Gen-2 and Gen-3 next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman, and Israel. Additional information about the Company is available at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2024 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
FAQ
What did Nexalin (NXL) announce on November 13, 2025 regarding Israel?
What indications did the Israeli Ministry of Health approve for Nexalin's Gen-2 SYNC (NXL)?
What responsibilities will Carmi Masha have under the NXL distribution deal?
Will Nexalin expand Gen-2 SYNC (NXL) applications beyond approved indications in Israel?
Does the NXL announcement include launch timing or sales guidance for Israel?
How does the Israel distribution deal affect Nexalin’s (NXL) international expansion?
